Head and Neck Squamous Cell Carcinoma and EBC-46: What the Phase II Data Reveals

Why Head and Neck SCC Is a Priority Target

Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 900,000 new cases worldwide each year. While most are treated with surgery, radiation, or systemic therapy, a subset of patients presents with superficially accessible cutaneous or mucosal lesions that are difficult to resect without significant morbidity — particularly in elderly patients or those with comorbidities that preclude general anaesthesia.^[1] This is precisely the clinical scenario where an intratumoral agent like tigilanol tiglate could fill an unmet need.

The rationale for targeting HNSCC extends beyond accessibility. These tumours are highly vascularised, making them theoretically susceptible to the vascular disruption component of EBC-46's mechanism. They also tend to have an immunologically active microenvironment, which could amplify the immune recruitment cascade triggered by PKC activation.

Trial Design and Patient Cohort

The Phase II programme for tigilanol tiglate in HNSCC enrolled patients with cutaneous or superficially accessible squamous cell carcinoma lesions. Eligibility criteria included measurable disease amenable to intratumoral injection, adequate organ function, and either failure of or unsuitability for standard treatment options.^[2] The primary endpoint was objective response rate assessed by RECIST criteria, with secondary endpoints including duration of response, time to response, and safety.

Treatment followed a defined injection protocol based on tumour volume, with lesions receiving calculated doses of tigilanol tiglate delivered under image guidance where necessary. Most patients received between one and three treatment cycles, with response assessments performed at standardised intervals.

Safety Profile

Consistent with the Phase I data, the most common adverse events were localised: injection site pain, localised oedema, and eschar formation at the treatment site.^[3] These events reflect the expected pharmacological activity of the drug — tissue necrosis and wound healing at the injection site — rather than off-target toxicity. Systemic adverse events were uncommon and generally mild, a marked contrast to the toxicity profiles associated with systemic chemotherapy or radiation to the head and neck region.

Response Data and Clinical Observations

Preliminary Phase II data demonstrated measurable responses in a proportion of treated lesions, with some patients achieving complete resolution of injected tumours. The time to initial response was characteristically rapid — visible changes at the injection site were often apparent within 48 to 72 hours — consistent with the known pharmacodynamics of PKC activation and vascular disruption.^[4]

The wound healing process following tumour necrosis was a notable observation. Despite the destruction of tumour tissue, treated sites typically healed with acceptable cosmetic outcomes — an important consideration for head and neck lesions where disfigurement carries significant psychological and functional impact. This clean healing response is attributed to the self-limiting nature of the inflammatory cascade, which resolves once necrotic tissue has been cleared.^[5]

Implications for Future Trial Design

The HNSCC data informs several aspects of ongoing trial design. First, the safety profile supports dose escalation studies to determine whether higher doses might improve response rates in larger lesions. Second, the rapid onset of response suggests that imaging endpoints could be assessed earlier than in conventional oncology trials, potentially accelerating development timelines.^[6]

The data also raises the question of combination approaches. Given that tigilanol tiglate generates a local immune response, combining it with checkpoint inhibitors — which are already standard of care in recurrent HNSCC — could enhance both local and systemic anti-tumour activity. Early-stage discussions around such combination protocols are underway.

References

1. ClinicalTrials.gov — tigilanol tiglate search ClinicalTrials.gov ↗
2. Panizza et al. (2019) — Phase I intratumoral tigilanol tiglate study PubMed ↗
3. Panizza et al. (2019) — safety and tolerability data PubMed ↗
4. Boyle et al. (2014) — Intratumoral EBC-46 in preclinical models PubMed ↗
5. De Ridder et al. (2021) — Tigilanol tiglate wound healing PubMed ↗
6. QBiotics Group — clinical development pipeline QBiotics ↗